Concepedia

Abhilasha Nair

AN

8

Publications

506

Citations

8

H-Index

2015

Active since

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Center for Devices and Radiological Health

Abhilasha Nair is an author at Center for Drug Evaluation and Research specializing in cancer therapeutics, oncology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2015–2023

8

Publications

8

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma

Denise Casey, Suzanne Demko, A. K. Sinha et al. · Clinical Cancer Research · 2021 · 99 citations

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Mirat Shah, Christy Osgood, Anup Amatya et al. · Clinical Cancer Research · 2022 · 86 citations · Full text

FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma

Abhilasha Nair, Kelie Reece, Martha Donoghue et al. · The Oncologist · 2020 · 81 citations · Full text

, , +14

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer

Abhilasha Nair, Steven J. Lemery, Jun Yang et al. · Clinical Cancer Research · 2015 · 76 citations

, , +17

FDA Approval Summary: Selpercatinib for the Treatment of Advanced <i>RET</i> Fusion-Positive Solid Tumors

Elizabeth S. Duke, Diana Bradford, Michelle Marcovitz et al. · Clinical Cancer Research · 2023 · 71 citations · Full text

Rows per page

1–5 of 8